CLEC11a Bone Growth Agent Osteoporosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for osteoporosis and bone diseases primarily focus on reducing bone loss rather than promoting new bone formation, and existing treatments have limitations such as side effects and limited duration of use, highlighting a need for improved methods to stimulate bone density, strength, and formation.
Innovation Solution
The use of CLEC11a or its agonists/mimics to promote osteogenesis, administered through various delivery methods including lipid vehicles, hydrogels, or nanoparticles, to enhance bone formation and treat bone-related disorders by targeting mesenchymal stem cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If current therapies for osteoporosis and bone diseases are used to reduce bone loss, then bone density is maintained, but new bone formation is not promoted and treatment duration is limited
Solution Approach 1:
The patent uses CLEC11a as an intermediary molecule that mediates the interaction between growth factors and mesenchymal stem cells to promote bone formation. CLEC11a acts as a signaling mediator that activates osteogenic differentiation pathways, enabling sustained bone formation without the limitations of current direct bone loss reduction therapies
Solution Approach 2:
The patent changes the biological parameter of mesenchymal stem cell differentiation by introducing CLEC11a, which shifts the cellular state from undifferentiated or adipogenic toward osteogenic lineage. This parameter change in cell differentiation status enables continuous bone formation and extends treatment duration beyond current therapies
2Stability of the object's composition
If existing bone treatments are administered, then bone loss is reduced, but side effects and limited duration of use occur
Solution Approach 1:
The patent employs CLEC11a to enable mesenchymal stem cells to self-differentiate into osteoblasts and self-organize to form new bone tissue. This self-service mechanism eliminates the need for external interventions that cause side effects, as the body's own cells perform the bone formation function naturally
Solution Approach 2:
CLEC11a serves as a safe intermediary that naturally activates endogenous bone formation pathways without introducing harmful substances. The mediator approach allows the body to produce bone through its own cellular mechanisms, avoiding the side effects associated with exogenous bone formation stimulants
3Strength
If CLEC11a or its agonists/mimics are administered to promote osteogenesis, then bone density, strength, and volume increase, but delivery complexity increases
Solution Approach 1:
The patent utilizes porous hydrogel matrices as delivery vehicles for CLEC11a. The porous structure provides high surface area for drug loading, enables controlled release kinetics, and maintains a simple overall delivery system architecture while achieving effective bone strength enhancement
Solution Approach 2:
The patent changes the physical state or formulation parameters of CLEC11a delivery by using lipid vehicles or hydrogels, which simplify the delivery system compared to nanoparticle approaches. These parameter changes in delivery formulation maintain therapeutic efficacy while reducing device complexity
Data Source
AI summary
The present disclosure describes the C-type lectin CLEC11a as a bone growth factor. Clec11a-deficient mice showed reduced bone volume and mineralization, while bone resorption remained unchanged. Administration of recombinant Clec11a systemically promoted bone formation in mice at risk for osteoporosis.